Sheraton Grand at Wild Horse Pass
5594 W Wild Horse Pass Blvd
Phoenix, AZ 85226
During this 3 day CME course, experts in the field of cardiovascular genetics detail the important role of genetics, genomics, and pharmacogenetics in the diagnosis, risk stratification, and treatment of diseases affecting the heart and the blood vessels.
Topics covered will include, Genetics Genomics 101, pharmacogenetics, polygenic risk scores, variant interpretation, the molecular autopsy, and the diagnostic, prognostic, & therapeutic implications of genetic testing for patients with congenital heart disease, long QT syndrome, Brugada syndrome, hypertrophic/dilated/arrhythmogenic cardiomyopathy, coronary heart disease, hyperlipidemias, heart failure, pulmonary hypertension, cardiac amyloid, and the aortopathies.
Unique Features: Audience response system to enhance immediate feedback. Easy access to faculty members. One-on-one interaction. Efforts will be made to introduce the clinical applications using new technology, however, there is no hands-on experience provided. Self-assessment questions to gauge outcome. A special workshop will be conducted to analyze a genetic test report and to comment on the significance of genetic test results from your patients.
To reinforce the knowledge gained from the course and ensure lasting value to each attendee’s practice, Mayo Clinic provides access to all course presentations with voice-over recordings after the completion of the course.
COURSE LEARNING OBJECTIVES
Upon conclusion of this program, participants should be able to:
- Summarize the probabilistic nature of genetic testing and develop a strategy to manage the variant of uncertain significance (VUS) test result
- Identify the impact of genetic testing in the diagnosis, risk stratification, and treatment of patients with heritable cardiomyopathies, channelopathies, pulmonary hypertension, cardiac amyloidosis, and aortopathies
- Determine the role of genetic testing in children and adults with congenital heart disease
- Define genetic markers of atherosclerosis and the role of genetic risk scores (GRS) in risk stratification of coronary heart disease
- identify the genetic basis of heritable lipid disorders and implications for prevention and familial screening
- Define the role of pharmacogenetics in cardiovascular drug response and to utilize pharmacogenetics testing to minimize adverse events and maximize drug efficacy
This course is intended for both pediatric and adult cardiologists, internists, primary care providers, and pharmacists, and nurse practitioners with special interest in the management of patients with genetic heart and vascular disease, pediatric and adult cardiology trainees, PAs and genetic counselors with an interest in genetic cardiovascular medicine.